Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.
about
The molecular targets of approved treatments for pulmonary arterial hypertensionPathobiology of pulmonary arterial hypertension and right ventricular failureOptimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment courseThe genetics of pulmonary arterial hypertensionThe German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)Recent advances in the management of pulmonary arterial hypertensionPulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatricsSmooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertensionPulmonary Arterial Hypertension and the Sex Hormone Paradox.Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocolPulmonary arterial hypertension: the clinical syndrome.BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysisPresence and outcomes of kidney disease in patients with pulmonary hypertensionOxidative profiling of the failing right heart in rats with pulmonary hypertensionThe right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertensionEstrogen receptor-dependent attenuation of hypoxia-induced changes in the lung genome of pulmonary hypertension rats.Follow-up tricuspid annular plane systolic excursion predicts survival in pulmonary arterial hypertension.Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challengesFrom short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertensionShort-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension.Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesicsSaudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updatesPulmonary arterial hypertension in Saudi Arabia: Patients' clinical and physiological characteristics and hemodynamic parameters. A single center experience.Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man.Heart rate slopes during 6-min walk test in pulmonary arterial hypertension, other lung diseases, and healthy controlsUnique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registrySkeletal muscle abnormalities in pulmonary arterial hypertension.Pulmonary hypertension in women.Echocardiographic assessment of estimated right atrial pressure and size predicts mortality in pulmonary arterial hypertension.An official American Thoracic Society Statement: pulmonary hypertension phenotypesComplete therapeutical approach in pulmonary arterial hypertension: from vasodilators to lung transplantation - case reportHospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational studySerum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.Effect of acute arteriolar vasodilation on capacitance and resistance in pulmonary arterial hypertension.Elevated plasma CXCL12α is associated with a poorer prognosis in pulmonary arterial hypertension.The sexual dimorphism associated with pulmonary hypertension corresponds to a fibrotic phenotypeThe genetics of pulmonary arterial hypertension in the post-BMPR2 era.Progress in the understanding and management of pulmonary arterial hypertension.Survival in an incident cohort of patients with pulmonary arterial hypertension in Denmark.Current clinical management of pulmonary arterial hypertension
P2860
Q26798308-5F2BEA03-33CA-4BBE-B63D-1447131303ACQ26821779-ACB31E76-06E4-4059-90E7-FE81175BBD3CQ27023074-8AC9A062-E8D0-4D7B-9160-F00379F50EAFQ27027507-83A4B3A0-E0BA-4DA6-960E-97DF6E9CEFA1Q27497418-379B6463-F06B-497B-9A44-52C5472DB95CQ28075707-164DF882-1A71-4230-8585-4B8338A6066DQ28085572-91189B4D-C1A5-4A2A-8663-EBD3856326E3Q28730183-B35FE813-6990-4635-B308-3CD29FAB546EQ30241478-9580C960-8150-4C3F-BCE9-98AA71579E94Q30490484-5AC8DA27-641E-4A05-AB8C-ACB44D6E688DQ30583630-48857BB6-DF8A-43A2-ABEF-B6AC6629A7F7Q31038854-DDA49E2B-3F80-4A93-8682-7C52B0D0F21DQ33571852-D270C2F4-2A6A-4692-A1BC-7889891344A6Q33637652-5AFA054F-E6BC-4FA0-AB51-D6B41179A9D9Q33702614-A7E929AC-3892-431E-893B-3FC728A232FEQ33738546-476BAF4C-C863-470C-A373-D16759CCB265Q33788434-41AB9B78-DED2-404E-898C-3BB93D8F0410Q33788582-99792545-EF49-4170-BC92-DB6162997A1DQ33806102-E854631E-315D-42DD-93D9-786EBB5155F0Q33806163-9397653D-AEBD-4A41-8F30-A5343AB88A23Q33806168-7875D516-A5F9-4EE2-90C3-5991F0ED238DQ33965904-313CBACC-A9C5-42DB-B2C9-09793B5B9601Q34197167-8FC7C739-3C58-4298-8A80-3057447FB778Q34245617-8AAB7EAD-E82F-41D6-8C0D-03480EAD9408Q34399959-2CBB6878-CE44-4C31-9522-1F89C4010C69Q34609902-41965DFA-DFC1-4048-83CC-EF046B57E785Q34611424-FB93B004-36A6-4348-8548-D22B3A92F8B1Q34795939-C5B598D2-F139-45A3-A9CA-9D383633ED42Q34840356-A0044B7F-0567-4F58-9D49-CF6616FE53D4Q34919733-BB8FBDB4-9918-4B45-A33D-1E7F1E182404Q34976912-28D4FBA6-F218-43DE-BD28-CC3ECF3580D8Q35041528-D82E2487-26C8-4506-9AEC-8C794B8C2F0CQ35140747-CDCF1D63-4AFB-4A7B-BE4B-BA6BBBC52BEDQ35298544-F28D66B4-5EE8-4419-9CEA-B6CCCEE36B32Q35346528-25D75CF3-97E8-4C83-8682-3A04AD780EA7Q35517586-62A32238-6B1C-45C7-922E-63B936CA4EB1Q35573919-73381660-2344-47FA-81E7-09D13FC172AEQ35662646-23306158-D25C-433B-97DA-7E6E40ECB6D0Q35665782-C55D03CA-6F29-47DC-96C7-5A4F8D588871Q35673783-D617DCC3-08A9-455C-9C61-808EA5B491AD
P2860
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Survival in incident and preva ...... lmonary arterial hypertension.
@en
Survival in incident and preva ...... lmonary arterial hypertension.
@nl
type
label
Survival in incident and preva ...... lmonary arterial hypertension.
@en
Survival in incident and preva ...... lmonary arterial hypertension.
@nl
prefLabel
Survival in incident and preva ...... lmonary arterial hypertension.
@en
Survival in incident and preva ...... lmonary arterial hypertension.
@nl
P2093
P50
P1476
Survival in incident and preva ...... ulmonary arterial hypertension
@en
P2093
D S O'Callaghan
French Pulmonary Arterial Hypertension Network
G Simonneau
J-F Cordier
P304
P356
10.1183/09031936.00057010
P577
2010-06-18T00:00:00Z